Abstract
Hepatocellular carcinoma (HCC) is the vital cause of cancer -related death throughout the world. At present, the exact mechanism responsible for the formation of HCC and its maintenance remains suspicious. Hepatocarcinogenesis involves a multistep activity involving several genetic aberrations which result in malignant transformation of the liver cells. The prevalence and occurrence of this disease are kept on increasing and an increase in the liver transplantation cases are vital indications for it. In the past decades, significant progress has been achieved toward the better elucidation of molecular pathways of oncogenic processes. Several, cell signaling mechanisms involved in tumor pathogenesis have been identified, leading to the production of new tumor markers and to set targets for therapy, including cytokines, enzymes, proteantigens. However, more tumor markers are in need for the effective early diagnosis of the disease condition and monitor the treatment efficacy. This review updates the recent findings in key molecular markers, pathways involved, animal models and treatment strategies in HCC and the advances obtained from basic research and clinical studies.
Keywords: Hepatocellular carcinoma, vascular endothelial growth factor, endothelial growth factor, carcinoembryonic antigen, trans-arterial chemoembolization.
Current Pharmaceutical Design
Title:An Updated Portrait of Pathogenesis, Molecular Markers and Signaling Pathways of Hepatocellular Carcinoma
Volume: 23 Issue: 16
Author(s): Muthukumaran Jayachandran *
Affiliation:
- Division of Science and Technology, Beijing Normal University-Hong Kong Baptist University, United International College, 28, Jinfeng Road, Tangjiawan, Zhuhai- 519085, Guangdong,China
Keywords: Hepatocellular carcinoma, vascular endothelial growth factor, endothelial growth factor, carcinoembryonic antigen, trans-arterial chemoembolization.
Abstract: Hepatocellular carcinoma (HCC) is the vital cause of cancer -related death throughout the world. At present, the exact mechanism responsible for the formation of HCC and its maintenance remains suspicious. Hepatocarcinogenesis involves a multistep activity involving several genetic aberrations which result in malignant transformation of the liver cells. The prevalence and occurrence of this disease are kept on increasing and an increase in the liver transplantation cases are vital indications for it. In the past decades, significant progress has been achieved toward the better elucidation of molecular pathways of oncogenic processes. Several, cell signaling mechanisms involved in tumor pathogenesis have been identified, leading to the production of new tumor markers and to set targets for therapy, including cytokines, enzymes, proteantigens. However, more tumor markers are in need for the effective early diagnosis of the disease condition and monitor the treatment efficacy. This review updates the recent findings in key molecular markers, pathways involved, animal models and treatment strategies in HCC and the advances obtained from basic research and clinical studies.
Export Options
About this article
Cite this article as:
Jayachandran Muthukumaran*, An Updated Portrait of Pathogenesis, Molecular Markers and Signaling Pathways of Hepatocellular Carcinoma, Current Pharmaceutical Design 2017; 23 (16) . https://dx.doi.org/10.2174/1381612823666170329124852
DOI https://dx.doi.org/10.2174/1381612823666170329124852 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry Second Generation Proteasome Inhibitors in Multiple Myeloma
Anti-Cancer Agents in Medicinal Chemistry Nucleoside Phosphorylases
Current Organic Chemistry Advances in the Molecular Detection of ABC Transporters Involved in Multidrug Resistance in Cancer
Current Pharmaceutical Biotechnology The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
Current Pharmaceutical Design Lysine Acetyltransferases CBP and p300 as Therapeutic Targets in Cognitive and Neurodegenerative Disorders
Current Pharmaceutical Design Combined Cancer Therapy with Non-Conventional Drugs: All Roads Lead to AMPK
Mini-Reviews in Medicinal Chemistry GSK3 Inhibitors and Disease
Mini-Reviews in Medicinal Chemistry Counter-Regulatory Role of Bile Acid Activated Receptors in Immunity and Inflammation
Current Molecular Medicine Designing Multiple Ligands – Medicinal Chemistry Strategies and Challenges
Current Pharmaceutical Design Diagnostic Imaging of Hepatocellular Carcinoma - A Pictorial Essay
Current Medical Imaging Blockade of Insulin-Like Growth Factor Type-1 Receptor with Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers
Current Drug Targets Update on the Development of microRNA and siRNA Molecules as Regulators of Cell Physiology
Recent Patents on DNA & Gene Sequences Status of Flavonols as P-Glycoprotein Inhibitors in Cancer Chemotherapy
Current Cancer Therapy Reviews Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy
Current Pharmaceutical Design Exploring the Mitochondrial Apoptotic Cell Death Landscape and Associated Components Serving as Molecular Targets, Primarily for Synthetic and Natural Drugs Targeting Oncology Therapeutics
Current Molecular Pharmacology Biology and Impact of Signal Transducers and Activators of Transcription and Their Regulators as Targets in Cancer Therapy
Current Signal Transduction Therapy MICA Gene and Relevance to Immune Responses in Organ Transplants and Inflammatory, Tumoral and Autoimmune Diseases
Current Immunology Reviews (Discontinued) Differential Involvement of Myosin II and VI in the Spontaneous and SDF- 1-induced Migration of Adult CD133+ Hematopoietic Stem/Progenitor Cells and Leukemic Cells
Current Cancer Therapy Reviews Anthraquinones: Analytical Techniques as a Novel Tool to Investigate on the Triggering of Biological Targets
Current Drug Targets